NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $11.31 -0.34 (-2.92%) Closing price 04:00 PM EasternExtended Trading$11.47 +0.16 (+1.45%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evolus Stock (NASDAQ:EOLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evolus alerts:Sign Up Key Stats Today's Range$10.88▼$11.7350-Day Range$9.36▼$14.8852-Week Range$8.67▼$17.82Volume769,437 shsAverage Volume667,901 shsMarket Capitalization$719.17 millionP/E RatioN/ADividend YieldN/APrice Target$23.75Consensus RatingBuy Company OverviewEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More… Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 77% of companies evaluated by MarketBeat, and ranked 231st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 4 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.90% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Evolus has recently increased by 7.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.27 Percentage of Shares Shorted12.90% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Evolus has recently increased by 7.27%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment1.60 News SentimentEvolus has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Evolus this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $794,369.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Stock News HeadlinesEvolus: Two-Product Aesthetics Company With A Competitive EdgeApril 22, 2025 | seekingalpha.comEvolus (NASDAQ:EOLS) Earns Buy Rating from Analysts at BTIG ResearchApril 20, 2025 | americanbankingnews.comWho’s really running AmericaMost Americans have never heard his name… He was instrumental in Trump’s victory. He turned J.D. Vance from a Trump-hater into his vice president. He’s one of the driving forces behind the rise of cryptocurrencies, digital commerce, social media, Big Data, cloud computing, and artificial intelligence... In other words, he’s America’s puppet master. April 28, 2025 | Porter & Company (Ad)Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2025 | businesswire.comBTIG Initiates Coverage of Evolus (EOLS) with Buy RecommendationApril 18, 2025 | msn.comEvolus initiated with a Buy at BTIGApril 17, 2025 | markets.businessinsider.comEvolus Announces Commercial Launch of Evolysse™April 17, 2025 | finance.yahoo.comEvolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid GelsApril 15, 2025 | finance.yahoo.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $11.04 at the start of the year. Since then, EOLS shares have increased by 2.4% and is now trading at $11.31. View the best growth stocks for 2025 here. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18. The firm earned $20.58 million during the quarter, compared to analysts' expectations of $20.60 million. Evolus had a negative net margin of 22.33% and a negative trailing twelve-month return on equity of 847.60%. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional shareholders include Assenagon Asset Management S.A. (1.12%), Rhumbline Advisers (0.13%), GAMMA Investing LLC (0.03%) and Teacher Retirement System of Texas (0.02%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, David N Gill and Robert Hayman. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings3/23/2021Today4/28/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$23.75 High Stock Price Target$27.00 Low Stock Price Target$21.00 Potential Upside/Downside+115.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-22.33% Pretax Margin-22.20% Return on Equity-847.60% Return on Assets-22.15% Debt Debt-to-Equity Ratio20.58 Current Ratio2.47 Quick Ratio2.23 Sales & Book Value Annual Sales$266.27 million Price / Sales2.64 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-30.65Miscellaneous Outstanding Shares63,587,000Free Float59,458,000Market Cap$701.68 million OptionableOptionable Beta0.97 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:EOLS) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.